Acute coronary syndrome and myocardial infarction
99 results
1 - 99
Acute coronary syndrome and myocardial infarction - Diagnostic coronary angiography
- Coronary heart disease
Pain severity does not predict outcomes with AMI- For treatment of acute coronary syndrome, prasugrel is better than ticagrelor at preventing recurrent MIs at 1 year
- High-sensitivity troponin I of less than 5 ng/L has negative predictive value of 99.9% for cardiac death at 1 year
Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome New- Bivalirudin = abciximab + heparin for non-STEMI
- Statins for acute coronary syndrome
- Routine or selective invasive strategy for acute coronary syndrome
- Adding ezetimibe to moderate-dose statin reduces nonfatal MI only (NNT = 58 for 6 years)
- Patients with non-ST-elevation acute coronary syndromes do not need immediate intervention
- Signs and symptoms not helpful in diagnosis of AMI/ACS
- Mortality rate in patients with recent ACS and endoscopy is similar to that in patients with ACS and no endoscopy
- Dyspepsia
- Escitalopram reduces risk of adverse cardiac events in adults with depression and acute coronary syndrome
- Apixaban increases bleeding with no benefit in high-risk patients with ACS
- Coronary CT angiogram allows for safe discharge of low-risk patients with chest pain
- Statins for acute coronary syndrome Stable (no update expected for reasons given in 'What's new')
- Hyperbaric oxygen therapy for acute coronary syndrome New search for studies and content updated (no change to conclusions)
- Similar outcomes after PCI in hospitals with or without on-site cardiac surgery (CPORT-E)
- Exercise stress test
- Antiplatelet agents for chronic kidney disease Edited (no change to conclusions)
- Ruling out acute myocardial infarction based on patient characteristics
- Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes: Cochrane systematic review
- Accelerated protocol identifies chest pain patients at low risk for major cardiac events
- In ACS, 5 yrs of invasive tx decreases MI but not all cause mortality (FRISC-II)
- Additional testing of limited benefit in patients with new-onset chest pain
- Two-hour protocol identifies patients at low risk of ACS
- Adding CCTA to chest pain assessment reduces likelihood of nonfatal MI (SCOT-HEART)
- Intensive lipid lowering reduces mortality following ACS
- Platelet-function testing doesn't improve outcomes in elderly patients with stents after ACS
- Single nondetectable high-sensitivity troponin result rules out AMI
- Flu vaccine reduces risk of adverse CV events in high-risk patients
- ACC/AHA guidelines on dual antiplatelet therapy
- Dabigatran associated with increased risk of coronary events
- Pioglitazone does not increase cardiovascular events (PROactive)
- Low-dose rivaroxaban improves outcomes in patients with ACS (ATLAS)
- Warfarin therapy
- Genotype-guided selection of oral P2Y12 inhibitor therapy no better than standard therapy after PCI for ACS or stable CAD
- FDA: Clopidogrel/aspirin does not decrease overall mortality
- Low HS-troponin I accurate in identifying patients at low risk of cardiac events
- PSK9 inhibitor alirocumab reduces nonfatal MI in patients after acute coronary syndrome, but at high cost (ODYSSEY OUTCOMES)
- Acute abdomen in the adult
- Percutaneous transluminal coronary angioplasty with stents versus coronary artery bypass grafting for people with stable angina or acute coronary syndromes: Cochrane systematic review
- CCTA reduces need for hospitalization in low to moderate risk patients in ED
- Improved outcomes with early invasive strategy for ACS? Maybe, maybe not.
- Better medication adherence with intervention; clinical outcomes unchanged
- Ticagrelor (Brilinta) is no better than aspirin—and may be worse—for adults after CABG
- Drug treatment for hypertension
- Dyspnoea
- For atrial fibrillation with ACS or PCI, apixaban plus clopidogrel (without aspirin) is preferred (AUGUSTUS)
- Omega‐3 fatty acids for the primary and secondary prevention of cardiovascular disease New search for studies and content updated (conclusions changed)
- Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion: Cochrane systematic review
- Early invasive therapy better for non-ST ACS
- 6-month clopidogrel better than 24 after stent placement (PRODIGY)
- ED chest pain protocol is safe and efficient
- B vitamins, fish oil do not prevent CV events
- Interpretation of adult ECG
- In patients with vascular disease, treating sleep apnea does not reduce the risk of cardiovascular events
- Little if any benefit to early invasive strategy for stable angina and at least moderate reversible ischemia (ISCHEMIA trial)
- Niacin not effective in CAD with low HDL cholesterol (AIM-HIGH)
- SBP of 120 instead of 140 in nondiabetic, high-risk elderly leads to significant benefits and some harms (SPRINT)
- Lipid lowering is beneficial for secondary prevention but not primary prevention in patients 75 years and older
- Increased readmissions and adverse events with intensification of antihypertensive regimen on hospital discharge
- Syncope: causes and investigations
- SBP of 120 instead of 140 in adults 75 years or older = significant benefits and some harms (SPRINT)
- Management of acute atrial fibrillation
- Final report from SPRINT: lowering SBP below 120 mm Hg decreases major adverse cardiac events and all-cause mortality
- Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events: Cochrane systematic review
- Prehospital emergency care
- Overview of new ACC/AHA lipid guidelines: here we go again
- The most common types of acquired adult valvular heart diseases and associated murmurs